⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 1, 2024International Journal of NanomedicineOpen Access

Combined ROS Sensitive PEG-PPS-PEG with Peptide Agonist for Effective Target Therapy in Mouse Model

Pingping Xiang Qi Liu Wangwei Jing Yaping Wang Hong Yu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Growth hormone-releasing hormone (GHRH) agonist, a 29-amino acid peptide, shows significant potential in treating myocardial infarction (MI) by aiding the repair of injured heart tissue. The challenge lies in the effective on-site delivery of GHRH agonist. This study explores the use of a targetable delivery system employing ROS-responsive PEG-PPS-PEG polymers to encapsulate and deliver GHRH agonist MR409 for enhanced therapeutic efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xiang et al. (2024) studied this question.

synapsesocial.com/papers/68e59c4cb6db643587536747 https://doi.org/10.2147/ijn.s471036

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fractionpreclinical · 2023 · 15 citations
2Efficacy of a Growth Hormone-Releasing Hormone Agonist in a Murine Model of Cardiometabolic Heart Failure with Preserved Ejection Fractionpreclinical · 2022 · 2 citations
3Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)preclinical · 2011 · 73 citations
4Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fractionpreclinical · 2022 · 26 citations
5Synthetic Growth Hormone-Releasing Hormone Agonist as Novel Treatment for Heart Failure with Preserved Ejection Fractionpreclinical · 2020 · 2 citations

More related papers

Design, Synthesis, and Preclinical Evaluation of a High-Affinity<sup>18</sup>F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction2024
Enhanced cardioprotective efficacy of <i>Rosmarinus officinalis-</i> loaded polydopamine nanoparticles for targeted therapy of myocardial infarction2025
New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor2015

More from International Journal of Nanomedicine

Nanoparticle-Based Therapeutic Strategies for Pathological Cardiac Hypertrophy: Preclinical Advances, Translational Challenges, and Future PerspectivesTue,
Enhanced Neuromodulation Using PC-CNTs and NIR Photothermal Therapy for Preventing Ventricular ArrhythmiasSat,